AROVELLA THERAPEUTICS LIMITED (ASX: ALA) — Perfil da empresa, notícias e dados financeiros
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer.
AROVELLA THERAPEUTICS LIMITED
AROVELLA THERAPEUTICS LIMITED is an Australia-based biotechnology company focused on developing invariant Natural Killer T (iNKT) cell therapies for the treatment of cancer. The company utilizes its proprietary CAR-iNKT cell therapy platform to create off-the-shelf, donor-derived therapeutics designed to target both blood cancers and solid tumors. Its lead research programs include CD19-targeted therapies for hematological malignancies and Claudin 18.2-targeted therapies for solid tumors such as gastric and pancreatic cancers. By combining chimeric antigen receptors with invariant T-cell receptor pathways and cytokine technology, the company develops multi-targeting cellular immunotherapies aimed at improving patient access and treatment outcomes.
Resumo
Operações
Produtos e/ou serviços de AROVELLA THERAPEUTICS LIMITED
- CD19-Targeting Cell Therapies: Development of allogeneic chimeric antigen receptor invariant Natural Killer T cell therapies directed against CD19 antigens for treating blood cancers, including non-Hodgkin lymphoma and B-cell leukemias in pediatric and adult patient populations.
- Claudin 18.2-Targeting Cell Therapies: Development of chimeric antigen receptor invariant Natural Killer T cell therapeutics engineered to target Claudin 18.2 expressers for the treatment of solid tumors, such as gastric and pancreatic cancers.
- Cytokine Enhancement Platform: Integration of membrane-anchored interleukin-12 cytokine technology into therapeutic cell constructs to improve cellular persistence, activation, and efficacy within immunosuppressive solid tumor microenvironments without systemic toxicity.
- Off-the-Shelf Allogeneic Cell Platform: Production of donor-derived invariant Natural Killer T cell therapies that do not induce graft-versus-host disease, providing scalable off-the-shelf cellular products for broader patient access compared to autologous treatments.
- CD1d-Mediated Dual-Targeting Platform: Utilization of invariant T-cell receptors to bind lipid antigens presented by CD1d molecules on tumor cells, enabling dual-action cancer targeting alongside chimeric antigen receptor mechanisms.
- Innate Cytotoxic Pathway Platform: Activation of natural killer cell receptor pathways, including NKG2D, to provide secondary tumor-killing capabilities and destroy immunosuppressive cells within the tumor microenvironment independent of targeted receptors.
equipe executiva do AROVELLA THERAPEUTICS LIMITED
- Nicole van der WeerdenActing Chief Executive Officer
- Lachie MalliaCFO & Company Secretary
- Michelle LongSenior Administration Manager
- Robson DossaSenior Vice President of Manufacturing & Quality
- Michelle FergusonSenior Director of Research & Development
Últimas notícias sobre a AROVELLA THERAPEUTICS LIMITED
Comunicados recentes
O que a AROVELLA THERAPEUTICS LIMITED (ALA) comunicou ao mercado, do mais recente para o mais antigo.
- Second Clinical Batch Released for Immediate Patient UseFato relevante
- Cell and Gene Innovation Spotlight Presentation
- Notice of Annual General Meeting/Proxy Form
- The path to first patient dosingFato relevante
Principais indicadores financeiros
Resultados divulgados pela AROVELLA THERAPEUTICS LIMITED, em AUD.
- Cap. de mercado
- 61,7 mi
- Receita (TTM)
- 3,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.0
- Dividend yield
- —
- Margem de lucro
- -197.7%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| — | -11,2 mi | -6,9 mi | |
| 136 mil | -11,2 mi | -7,5 mi | |
| 17 mil | -10,8 mi | -8,7 mi | |
| 405,9 mil | -9,7 mi | -10,2 mi |